While SGLT2 inhibitors have been extensively evaluated for their protective effects in heart failure through large-scale clinical trials such as the EMPA-REG OUTCOME trial, the CANVAS Program, and the DECLARE-TIMI 58 trial, their precise cardioprotective mechanisms remain a subject of ongoing investigation. The gene discussed is SLC5A2; the disease is heart failure.